Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 24, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 22, 2017The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
22 Mar 2017 KING OF PRUSSIA, Pa — 22 March 2017 Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied Data show up to 40% of HAE...
-
Mar 21, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 1, 2017PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy
01 Mar 2017 KING OF PRUSSIA, Pa — 01 March 2017 Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...
-
Feb 25, 2017
Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. 25 Feb 2017 The company, which is part of global...
-
Feb 22, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Feb 20, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Feb 14, 2017FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition
14 Feb 2017 KING OF PRUSSIA, Pa — 14 February 2017 Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
Feb 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Feb 10, 2017An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type...
-
Jan 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 11, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 9, 2017- CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A
09 Jan 2017 MARBURG, Germany — 09 January 2017 CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A The therapy has been specifically designed for greater...
-
Jan 9, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 5, 2017
05 Jan 2017 CAMBRIDGE, MA — 05 January 2017 Momenta to receive $50 million upfront license fee and up to 4550 million in potential milestone payments from CSL Momenta to host a conference call...
-
Dec 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 21, 2016CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.
21 Dec 2016 CSL Limited (ASX:CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16 report the top 15 sustainability...
-
Dec 14, 2016Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
14 Dec 2016 AFSTYLA is the first and only single-chain recombinant factor VIII for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In...
-
Dec 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 7, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases